Dr. David C. Larsen, MD
Family Medicine (Family Medicine Physician)
999 Murray Holladay Rd, Suite 207
Salt Lake City, UT 84117
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Utah School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 178
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Utah School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
UT license 30852741205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Intermountain Medical Center Murray, UT
- Intermountain Health Alta View Hospital Sandy, UT
- St Mark's Hospital Salt Lake City, UT
Medical groups
- Granger Medical Clinic PC (193 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 178
- Services billed
- 990
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 171 | 97 |
| Established patient office or other outpatient visit, 20-29 minutes | 131 | 71 |
| Annual depression screening, 5 to 15 minutes | 70 | 70 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 68 | 68 |
| Administration of influenza virus vaccine | 46 | 45 |
| Automated urinalysis test | 44 | 42 |
| Influenza vaccine split virus, preservative free | 43 | 42 |
| Hemoglobin a1c level | 32 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 64 payments worth $1,171 in total to this clinician.
| AbbVie Inc. | $202 |
|---|---|
| UCB, Inc. | $117 |
| Pfizer Inc. | $96.77 |
| Gilead Sciences, Inc. | $84.69 |
| Viiv Healthcare Company | $80.84 |
| Novo Nordisk Inc | $63.28 |
| Novartis Pharmaceuticals Corporation | $60.49 |
| AstraZeneca Pharmaceuticals LP | $57.75 |
| Food and Beverage | $1,171 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $291,332 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees
American Regent · Completed · NCT01925261 - Phase 3 multicenter randomized doubleblind group sequential placebocontrolled study to assess efficacy and safety of rimegepant for the treatment of migraine with or without aura in children and adolescents 6 to 18 …
Pfizer Inc. - Phase 3 multicenter openlabel study to assess the longterm safety and tolerability of rimegepant for the acute treatment of migraine with or without aura in children and adolescents 6 to 18 years of age
Pfizer Inc. - A phase 1 multicenter openlabel singledose study to evaluate the safety tolerability and pharmacokinetics of zavegepant in children 6 to less than 12 years of age with history of migraine
Pfizer Inc. - An interventional efficacy and safety phase 3 randomized doubleblind placebocontrolled study with an openlabel extension to investigate rimegepant in migraine prevention in adolescents 12 to less than 18 years of age …
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.